The right material.

The right resolution.

Next-gen in vitro models.

Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3Dprinted at a scale and resolution that was previously unattainable.

Our innovation 3DPDMS creates microfluidics in the industry-standard material at a speed and resolution to create true biological models that propel bioinnovation across the biotech industry.

Backed by two NIH grants, Phase, Inc. is currently working with Harvard Medical School, Georgia Tech, and Virginia Tech to develop a microfluidic device that will allow researchers to develop new brain cancer treatments.

With a team of seasoned leaders in both 3D printing and biomedical engineering with advanced degrees from MIT and UC Berkeley, Phase is poised to lead the microfluidics industry in unlocking the next wave of medical breakthroughs.

Phase in the News

Alumnus and engineer collaborate on 3D printing to advance microfluidic systems

Phase and Virginia Tech Partner To Advance Microfluidic 3D Printing

Local startup lands NIH grant for 3D-printing collaboration with Virginia Tech

Let's connect.

11148 Treynorth Drive, Suite A
Cornelius, North Carolina 28031